Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Monogram Biosciences has announced that, effective July 15, 2008, the HERmark breast cancer assay will be available to physicians throughout the US for assessment of HER2 status in patients with breast cancer.
Subscribe to our email newsletter
HERmark is said to be a proprietary diagnostic that accurately quantifies HER2 total protein levels and HER2 homodimerization in patients with breast cancer. According to the company, HERmark provides a precise and quantitative measurement of HER2 total protein and HER2 homodimer levels.
HERmark will be commercialized by Monogram through its direct sales and marketing organization and will be offered as a CLIA-validated assay through the company’s CAP-certified clinical laboratory.
William Young, Monogram’s CEO, said: “With HERmark, physicians now have a way to get an accurate and reliable quantitative measurement of their patients’ HER2 status to help guide personalized therapy. We are looking forward to further developing this technology in order to provide the oncology community other VeraTag based assays that will provide more comprehensive and accurate information on a individual patient’s tumor profile.”